Reduced lymphopoiesis during aging contributes to declines in immunity, but little consideration has been given to its effect on the development of hematological disease.
Introduction
Hematopoietic stem cells (HSC) are the precursors from which all mature blood cells are generated 1, 2 . HSC normally maintain the hematopoietic system through balanced differentiation into common myeloid (CMP) and lymphoid specified progenitors. CMP, the earliest myeloid specified progenitors to be defined, subsequently differentiate into granulocyte-macrophage (GMP) and megakaryocyte-erythroid progenitors (MEP) from which most myeloid and erythroid cells respectively arise 3 . While there is uncertainty regarding the characteristics of the most HSC proximal lymphoid specified progenitors 4 , there is general agreement that common lymphoid progenitors (CLP) 5 Recent analyses have shown that the balance of hematopoietic cell production becomes severely perturbed during aging. B lymphocyte development begins to decline early in adult life, and the production of B cells is dramatically diminished in aged individuals 8, 9 . This decline is manifest at all stages of B cell development, as both the frequency and number of CLP and their downstream pre-pro-B, pro-B, and pre-B cell progeny are significantly reduced with age [10] [11] [12] [13] [14] . Since HSC accumulate multiple functional defects with increasing age [15] [16] [17] [18] , it has been proposed that the decline in B lymphopoiesis is the result of age-related deficiencies in the potential of HSC to generate lymphoid progeny 19, 20 as well as to proliferative and differentiative defects intrinsic to lymphoid intermediates 9, 21 . Despite increasing evidence that aged HSC do not proliferate and differentiate as efficiently as their young counterparts 22 , myelopoiesis has been reported to be unaffected by aging 11, 19 . This conclusion is based on the finding that the frequency of CMP and their downstream progeny remains normal or is increased in old mice.
The consequences of HSC aging and reduced lymphocyte production have, for the most part, been considered in the context of their impact on the quality of the adaptive immune response, which is diminished in the elderly 23 . Less attention has been given to
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From how these age-related alterations influence disease within the hematopoietic system, and hematopoietic malignancies in particular 24 . For instance, the majority of leukemias that present in children involve lymphoid cells, and these occur at a time when lymphoid progenitor number and proliferation are highest 8, 11 . Conversely, myeloid leukemias tend to predominate in the elderly when lymphopoiesis is waning 19 .
CML, the most common MPD in humans, typifies this pattern 25 . CML presents as a myeloid hyperplasia that occurs almost exclusively in adults and its incidence increases with age. Over 90% of CML patients possess the Philadelphia chromosome 26, 27 , a reciprocal translocation t(9q34;22q11) 28 that fuses the breakpoint cluster region (BCR) and Abelson tyrosine kinase (ABL) genes [29] [30] [31] and encodes a 210 kDa chimeric protein with constitutive tyrosine kinase activity 30, 32 . The occurrence of the BCR-ABL P210 translocation in HSC [33] [34] [35] [36] has led to CML being classified as a disease of stem cell origin 37 . Since HSC have multilineage differentiation potential 38 , their transformation would be expected to result in disease with representation of both the myeloid and lymphoid lineages. However, this is not the case, since BCR-ABL P210 induced leukemia predominantly presents as CML and rarely causes disease with lymphoid involvement.
This clinical presentation of CML, combined with the fact that it is a disease of middle and old age 39 , led us to hypothesize that the age-related decline in lymphopoiesis is a factor that contributes to the myeloid predominance of this and other adult-onset leukemias. In order to test this premise, we examined the pattern of disease induced by 
Generation of retroviral stocks
The retroviral vector pMSCV 40 virus particles/ml.
Retroviral transduction and bone marrow transplantation
Young mice were administered a single intravenous dose of 5-Fluorouracil (5-FU, 150 mg/kg body weight; Sigma). Due to their higher susceptibility to 5-FU, middle-age and
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From old mice were administered a dose of 115 mg/kg body weight. On the eighth day after 5-FU administration, BM cell suspensions were prepared as described 42 . Cells were distributed in 5 ml polystyrene tubes (Becton Dickinson) and incubated with 1 ml of retrovirus supplemented with 10% horse serum (Hyclone), 1mM L-glutamine, 100 U/ml streptomycin, and 100 µ g/ml penicillin, 8 µ g/ml polybrene (Sigma), 50 µ M β -mercaptoethanol (Sigma), 25 mM HEPES (Gibco), 100 ng/ml SCF (Biosource), 100 ng/ml Flt-3L (R&D), and 10 ng/ml IL-11 (R&D) for 2 hours at 37 ºC in 5% CO 2 and air and constant humidity. Cells were centrifuged for 5 minutes at 400g, and viral supernatant was replaced with 1 ml of virus stock supplemented as described above. This procedure was repeated twice. After 6 hours, cells were washed, counted, and resuspended in PBS. Purified pro/pre-B cells were infected in a modified progenitor cell culture system 42 . One million cells were seeded in 6 well plates in RPMI 1640 (Gibco)
supplemented with 10% FCS, 1mM L-glutamine, 100 U/ml streptomycin, 100 µ g/ml 
Immunophenotypic analysis of leukemic cells and cell sorting
BM and spleen cell suspensions were prepared as previously described 42 Cells to be purified were resuspended in minimum essential medium-α (αMEM; Gibco) supplemented with 2% FCS, 25 mM Hepes, 1mM L-glutamine, 100 U/ml streptomycin, 100 µ g/ml penicillin, and 50 µg/ml gentamycin before being sorted on a FACSaria (Becton Dickinson). Sorted fractions were examined by reanalysis, and were routinely 95% pure. supplemented with 5% FCS, 50 µ M β -mercaptoethanol, 1 mM L-glutamine, 100 U/ml streptomycin, and 100 µ g/ml penicillin 45 . Cultures were incubated at 37 ºC in 5% CO 2 and air and constant humidity, and fed twice weekly for up to three weeks.
Myeloid cultures
Myeloid colony assays were performed by resuspending target cells in 1 ml of methylcellulose supplemented with 30% FCS, 40%
mM L-glutamine, 100 U/ml streptomycin, 100 µ g/ml penicillin, 50 µg/ml gentamycin, 20 ng/ml SCF, 10 ng/ml GM-CSF (Biosource), 30 ng/ml IL-3, and 10 ng/ml IL-11 in 3. µg/ml gentamycin, 20 ng/ml SCF, 10 ng/ml GM-CSF, 30 ng/ml IL-3, 30 ng/ml IL-6, and 10 ng/ml IL-11 at 37 ºC in 5% CO 2 and air and constant humidity. Cultures were fed on day 4, and on day 6 cells were harvested and assessed by immunostaining with Gr-1 and CD11b as described above.
Statistical analysis
Unless indicated otherwise, data are expressed as a mean ± SEM. Differences between groups were tested by a two-tailed, unpaired t-test, with an α of 0.05.
Results

Hematopoietic cell age alters BCR-ABL P210 induced leukemia phenotype
To assess the impact of aging on BCR-ABL P210 induced leukemogenesis 46 Disease patterns in BM BCR-ABL recipients were assessed by phenotypic and morphologic characterization of hematopoietic cells in their BM and spleen ( Figure 1D and Figure 1F ).
The incidence of B lymphoid leukemia correlates with age-related declines in B lymphopoiesis
The decline in B lymphopoiesis does not abruptly initiate in old age, but instead begins in relatively young animals and progresses gradually thereafter 8 If the age-related decline in B cell production underlies the reduced capacity of BM BCR-ABL cells to initiate B lymphoid leukemia, then the incidence of BCR-ABL P210 induced lymphoid disease should decline gradually with increasing age. This hypothesis was tested by transplanting BCR-ABL P210 transduced BM cells from young, middle-age, and old mice into Rag1 -/-recipients. As shown in Figure 2C, 
Cell intrinsic defects diminish the leukemogenic potential of aged B lineage cells
In addition to its emergence from HSC 36 , B lymphoid leukemia can also initiate from direct transformation of committed lymphoid progenitors [50] [51] [52] . This raised the possibility that the reduced incidence of B lymphoid leukemia from aged BM cells observed in the above study resulted from the lower number of lymphoid progenitors available for transformation ( Figure 2B ). However, this was not the case. When an equivalent number Figure 3E ).
Taken together, these observations indicate that BCR-ABL P210 expression cannot overcome the proliferative and differentiative defects that have accumuatled in aged B lymphoid precursors, and these defects underlie their reduced leukemogenic potential.
For 
Identification of myelopoietic defects in old mice
The above data were surprising because the frequency and absolute number of HSC and myeloid progenitors is increased in the BM of old mice ( Figure 5A ) 11, 19 . Therefore, we considered the possibility that aging affected the quality of old myeloid progenitors.
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Further analysis revealed that while old BM cells formed 1.3 fold more colonies than young BM cells, this value was less than would be predicted from the 2.3 fold increase in myeloid progenitor frequency observed by flow cytometry. This could be due in part to a 2-3 fold increase in the number of apoptotic Annexin V + CMP and GMP in old as compared to young BM ( Figure 5B ). In addition, individual colonies derived from old BM cells contained approximately 50% fewer cells than those derived from young BM cells ( Figure 5C ), and old CMP similarly generated smaller colonies than their counterparts from young mice ( Figure 5D ).
This age-related reduction in myelopoietic potential was also observed when whole BM cells or sorted CMP isolated from young and old mice were grown in liquid culture supplemented with myelopoietic cytokines. Consistent with results from the colony assays, BM cells ( Figure 5E ) and CMP ( Figure 5F ) from old mice produced approximately 45% less Gr-1 + CD11b + myeloid cells than those isolated from young animals. Taken together, these results demonstrate that aged myeloid progenitors harbor intrinsic proliferative and/or differentiative defects.
Age-related hematopoietic defects alter the potential of leukemia stem cells (LSC)
Hematopoietic stem and progenitor cells play a critical role in the pathogenesis of CML.
HSC have been implicated as the leukemic cell of origin, while committed myeloid and lymphoid progenitors have been deemed the LSC in more advanced stages of disease 36, 37, 53 . Consequently, we assessed whether age-related differences in the pathogenesis of BCR-ABL P210 induced leukemia was a reflection of changes intrinsic to LSC. Since LSC are defined by their potential to transplant disease 54, 55 , splenocytes isolated from diseased mice grafted with young or old BM BCR-ABL were transplanted into sublethally irradiated syngeneic mice. Disease patterns and progression were then analyzed in these secondary recipients.
Secondary recipients developed disease symptoms within 3 weeks posttransplantation and were sacrificed. All these mice (27/27) presented with MPDs.
However, 60% (9/15) of mice grafted with splenocytes from young BM BCR-ABL recipients also presented with B lymphoid leukemia ( Figure 6A ). In contrast, none (0/12) of the mice grafted with splenocytes from old BM BCR-ABL recipients developed lymphoid
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In addition, we compared secondary recipients that developed MPDs without B lineage involvement for disease severity. Leukemic burden was 3 fold greater in secondary recipients transplanted with young BM BCR-ABL derived tumors when compared with secondary recipients of old BM BCR-ABL derived tumors ( Figure 6C and 6D ). These data demonstrate that myeloid LSC derived from young BM BCR-ABL have a greater expansive potential through either enhanced self-renewal and/or increased production of mature leukemic myeloid progeny. Taken together, these data indicate that age-related intrinsic hematopoietic defects ultimately alter the leukemogenic potential of LSC generated following transformation of hematopoietic cells by BCR-ABL P210 .
Discussion
The present report demonstrates that age-related intrinsic defects that accumulate in B lineage cells limit lymphoid involvement in CML. This finding provides a biological explanation for the myeloid predominance of adult-onset leukemia. Although this study focused on B cell development, T cell production also declines with increasing age 21 , which may explain the extreme rarity with which T cell leukemia presents in older humans.
In the murine CML model used in this study, transformation of young BM cells proliferative and developmental defects in the progenitors that are generated, would contribute to a low incidence of lymphoid leukemia and a predomincance of myeloid disease in the aged. In contrast, young HSC efficiently generate lymphoid progeny, which in turn are highly susceptible to the effects of BCR-ABL P210 , thereby resulting in MPD and B lymphoid leukemia 56 .
Our finding that B lymphoid leukemia initiated more frequently with young than old BM BCR-ABL is consistent with the clinical observation that the incidence of B lineage leukemia is highest in children. That children are predisposed to lymphoid leukemia is consistent with results from murine studies demonstrating that B lineage progenitors from neonates and young adults cycle at levels above their aged counterparts 11 . While this increased proliferation may be necessary to fill peripheral lymphoid compartments, it could increase the chance that an aberrant genetic event could occur, particularly since developing B lineage cells possess active gene rearrangement machinery 57 . This possibility, combined with the presence of chromosomal translocations in neonatal B lineage progenitors that cause a predisposition to leukemia development 58 , may increase the likelihood of transformation during early B lymphopoiesis.
The observation that MPDs initiated from young BM BCR-ABL cells were more aggressive than those initiated from old BM BCR-ABL cells was quite unexpected. This pattern led to the discovery that defects do in fact accumulate in aged myeloid progenitors. Thus, it is reasonable to propose that the milder MPDs are the result of agerelated defects in growth and survival of myeloid progenitors and/or their progeny. It is surprising that age-related changes in myeloid progenitors were not previously reported.
However, previous studies primarily examined myeloid progenitors as a population rather than on a per-cell basis, and as a result, the cell intrinsic defects defined herein had been overlooked. The age-related defects that accumulate in myeloid progenitors are similar to the those exhibited by aged HSC, including increased frequency and cycling, decreased survival, and diminished per-cell repopulating potential 22 . These observations suggest that age-related defects intrinsic to myeloid progenitors may be the result of intrinsic changes in old HSC. However, whether old HSC and CMP share common molecular changes 59 remains to be determined.
While the detrimental effects of advancing age and decreased lymphocyte production on the adaptive immune response have been well documented 23 , the consequences of aging on the innate immune system remain largely unexplored 60 . The innate immune system is a critical first responder to infection. Despite defects in old myeloid progenitors, their increased number may compensate for the fact that they do not produce progeny as efficiently as their young counterparts, which results in a relatively normal number of mature myeloid cells. However, reports of diminished function of aged neutrophils 61 , macrophages 62 , and dendritic cells 63 indicates that the innate immune response may become significantly compromised with age. Consequently, the unexpected observation that myeloid progenitors from old mice are intrinsically defective suggests that age-related defects may contribute the overall reduction in myeloid cell function in the elderly.
While this study used CML as a model with which to investigate the larger question of how aging affects leukemia development, the data nevertheless provide new insights into this disease. First, the demonstration that the degree of lymphoid disease mediated by BCR-ABL P210 is related to overall levels of B lymphopoiesis provides an explanation for the paradoxical observation that while CML is considered a stem cell disease, it presents as a MPD with relatively rare lymphoid involvement. Second, agerelated defects in myeloid progenitors may explain in part why human CML presents with a chronic rather than an acute course 64 . Finally, we demonstrate that patterns of lymphoid and myeloid disease exhibited in primary recipients of young and old BM Figure 1F . 
